QM · rank #10 · 2026-09-07
SNT
GPW · PLN · $742M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +79.46% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $742M |
| Anchor (recent) Close on 2026-08-07 | $359.00 |
| Anchor (far) Close on 2025-08-08 | $200.05 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. is a Polish healthcare technology group that manufactures and distributes PET/CT radiopharmaceuticals while integrating advanced medical imaging and robotic surgery systems across Central Europe [RECENT_DEVELOPMENTS, BUSINESS_STATUS].
Rationale
The stellar quality-momentum signals are validated by strong operational execution, with H1 revenue up ~35% and core EBITDA up ~46%, supported by a robust geographic moat as Poland's sole supplier of key high-margin specialized tracers [COMPETITIVE_POSITION, FINANCIAL_NOTES].
Material risks
- 1Polish public hospitals and oncology centers building in-house cyclotrons and tracer production capabilities would directly bypass Synektik's logistics-based moat and erode its sole-supplier status [TOP_RISKS].
- 2Headline ROE and net income are temporarily distorted by a PLN 261m one-time gain from the Syn2bio spin-off, creating a risk of sharp optical normalization in subsequent quarters [RECENT_DEVELOPMENTS, TOP_RISKS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.